Abstract
Intra-operative insults may subject living kidney transplants to poor outcomes. Therefore, we investigated whether intra-operative recipient and donor hemodynamics could act as predictors of delayed graft function and subsequent outcomes.
Living kidney donors and recipients from 2010-2016 at this institution underwent a retrospective chart review. Graft function by post-operative day 7 was used to classify recipients as delayed graft function (need for dialysis), slow graft function (creatinine > 2.5) and good function. Groups were analyzed for intra-operative hemodynamic differences and at one year, incidence of rejection, graft function and survival were compared.
A total of 111 living renal transplants were performed. Average recipient age was 50 and just over halfwere male (53%). 9% (n=10) and 10% (n=11) developed delayed graft function and slow graft function, respectively. Minimum recipient post re-perfusion central venous pressure ≥12 mmHg was associated with poor graft function (delayed graft function/slow graft function/good function=67%/56%/24%,
This single center retrospective study suggests that a post re-perfusion central venous pressure ≥12 mmHg is associated with delayed graft function.
Author Contributions
Copyright© 2017
J. Schutt Ryan, et al.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests The authors have declared that no competing interests exist.
Funding Interests:
Citation:
Introduction
Living donors are the preferred source of kidneys for transplant as they offer better quality of life, graft- and patient survival
Results
A total of 111 living donors and recipients were evaluated, with recipient demographic data presented in a b c Represent the lower quartile a, the mean b, and the upper quartile c for continuous variables. Other/Unknown: Alport Syndrome (2), Reflux Nephropathy (3), Renal Cell Carcinoma (1), Unknown (7), Hypoplastic Kidney Disease (1), Lithium Toxicity (1), Immunoactoid Glomerulopathy (1); Autoimmune: IgA Nephropathy (10), Systemic Lupus Erythematosus (5). BMI, body mass index; BSA, body surface area; HLA, human leukocyte antigen. Notably, minimum CVP ≥12 mmHg was associated with poor graft function (DGF/SGF/GF= 67%/56%/24%, p=0.009) ( a b c Represent the lower quartile a, the mean b, and the upper quartile c for continuous variables. BSA, body surface area; BMI, body mass index The average donor age was 44, and groups were similar in age based on graft function ( Donor sex did not appear to influence recipient graft function, nor did gender mismatch. Most donors (n=62) were unrelated and the donor’s relationship to the recipient was not associated with graft function. Donors with grafts resulting in poor function were taller (p=0.03) and weighed more (p=0.02). However, donor BMI and body surface area were not related to graft function. Pre-operative creatinine of the donor had no bearing on graft function, nor did the presence of donor hypertension or blood type. There was no statistical association between donor estimated blood loss, total intra-operative fluid volume received, administration of albumin or furosemide. No association was found between donor intra-operative hypotension and graft function ( a b c Represent the lower quartile a, the mean b, and the upper quartile c for continuous variables. Intra-Operative Hypotension (systolic blood pressure <90 mmHg or diastolic blood pressure <50 mmHg in donor post renal artery clamp and in recipient post reperfusion); Minimum and Maximum Intra-Operative CVP (measured post reperfusion). CVP, central venous pressure. Regarding 1 year recipient outcomes ( a b c Represent the lower quartile a, the mean b, and the upper quartile c for continuous variables. BMI, body mass index; BSA, body surface area. Incidence of rejection within the first year and type of rejection 1 Year Graft Survival (number of patients with 1 year worth of follow up or that lost allograft prior to 1 year; DGF=7, SF=9, GF=75): no return to dialysis or patient death Comparison of creatinine trend over time between the three cohorts. SE(standard error).
Age (years)
11 1
48.365.5 72.0
43.051.0 67.0
38.348.5 60.0
0.027
Sex
11 1
0.018
Male
80% (8)
82% (9)
47% (42)
Female
20% (2)
18% (2)
53% (48)
Height (cm)
11 1
163.5 170.0 178.7
177.0182.0 185.5
160.3168.0 178.0
0.008
Weight (kg)
11 1
68.2 84.2 94.6
76.4103.5 114.5
58.775.5 86.9
0.008
BMI (kg/m2)
10 9
26.530.4 30.9
27.2 30.3 32.6
22.326.5 29.8
0.019
BSA (m2)
10 9
1.72.02.2
1.9 2.3 2.4
1.71.9 2.1
0.004
Pre-Operative Creatinine (mg/dl)
11 1
6.17.2 8.5
6.37.3 11.7
5.16.7 9.2
0.575
Primary Diagnosis
11 1
0.377
Diabetes
30% (3)
9% (1)
16% (14)
Hypertension
30% (3)
9% (1)
8% (7)
Polycystic Kidney Disease
10% (1)
36% (4)
18% (16)
Re-Transplant
0% (0)
9% (1)
4% (4)
Autoimmune
10% (1)
0% (0)
16% (14)
Glomerular Disease
20% (2)
18% (2)
23% (21)
Other/Unknown
0% (0)
18% (2)
16% (14)
Previous Transplant
11 1
0% (0)
18% (2)
9% (8)
0.346
Pre-Transplant Dialysis
11 1
100% (10)
73% (8)
70% (63)
0.128
Hemodialysis
11 1
90% (9)
27% (3)
31% (28)
<0.001
Peritoneal Dialysis
11 1
10% (1)
45% (5)
39% (35)
0.165
Blood Type
11 1
0.205
A
40% (4)
18% (2)
43% (39)
AB
0% (0)
9% (1)
1% (1)
B
20% (2)
9% (1)
22% (20)
O
40% (4)
64% (7)
33% (30)
PRA Class I Sensitized (>20%)
105
0% (0)
22% (2)
6% (5)
0.116
PRA Class II Sensitized (>20%)
105
20% (2)
11% (1)
6% (5)
0.255
Pre-formed Donor Specific Antibody
104
0% (0)
18% (2)
5% (4)
0.21
Any HLA Mismatch
110
67% (6)
91% (10)
87% (78)
0.232
n
DGF (n=10)
SGF (n=11)
GF (n=90)
p-value
Donor-Recipient Height Ratio (cm)
99
1.00 1.04 1.06
0.96 0.97 0.97
0.92 0.98 1.04
0.11
Donor-Recipient Weight Ratio (kg)
110
0.90 1.01 1.12
0.74 0.80 1.04
0.81 1.00 1.28
0.18
Donor-Recipient BSA Ratio (kg/m
96
0.99 1.03 1.11
0.84 0.87 0.96
0.86 1.00 1.12
0.09
Donor-Recipient BMI Ratio (m
97
0.91 0.99 1.09
0.82 0.85 0.96
0.90 1.02 1.23
0.18
n
DGF (n=10)
SGF (n=11)
GF (n=90)
p-value
Recipient
Cold Ischemic Time (min)
111
43.0 47.0 57.0
42.5 49.0 295.5
40.0 44.5 51.7
0.339
Warm Ischemic Time (min)
110
28.3 30.0 32.8
27.5 31.0 37.0
27.0 30.0 34.0
0.699
Estimated Blood Loss (ml)
93
37.5 100.0 100.0
50.0 100.0 100.0
50.0 50.0 100.0
0.901
Fluids (ml)
105
2000 2250 2700
2350 2800 3300
2275 3000 3325
0.124
Albumin Use
107
70% (7)
55% (6)
64% (55)
0.752
Mannitol Use
106
70% (7)
91% (10)
75% (64)
0.456
Lasix Use
107
100% (10)
100% (11)
92% (79)
0.401
Intra-Operative Hypotension
106
60% (6)
45% (5)
44% (37)
0.613
Minimum Intra-Operative CVP
85
0.009
< 12 mmHg
33% (3)
44% (4)
76% (51)
≥ 12mmHg
67% (6)
56% (5)
24% (16)
Donor
Estimated Blood Loss (ml)
68
35.0 50.0 50.0
27.5 50.0 50.0
20.0 50.0 50.0
0.605
Fluids (ml)
99
2000 2750 3000
2250 2750 3350
2300 2800 3200
0.779
Albumin Use
99
0% (0)
0% (0)
4% (3)
0.742
Lasix Use
101
88% (7)
100% (8)
74% (63)
0.191
Intra-Operative Hypotension
106
60% (6)
45% (5)
44% (37)
0.613
Age (years)
111
43.347.5 52.3
39.546.0 56.5
37.045.0 52.0
0.434
Sex
110
0.584
Male
60% (6)
55% (6)
45% (40)
Female
40% (4)
45% (5)
55% (49)
Height (cm)
99
164.3174.0 181.0
174.5177.5 180.1
157.8167.0 170.5
0.031
Weight (kg)
110
80.985.7 91.1
78.385.2 93.4
65.274.7 85.5
0.022
BMI (kg/m2)
99
26.827.2 29.2
24.725.9 27.9
24.027.1 28.8
0.644
BSA (m2)
98
1.92.0 2.1
1.92.0 2.0
1.71.8 2.0
0.147
Pre-Operative Creatinine (mg/dl)
108
0.80.8 0.9
0.80.9 1.0
0.70.8 1.0
0.481
History of Hypertension
67
20% (1)
50% (2)
16% (9)
0.218
Relationship to Recipient
111
0.498
First Degree Relative
30% (3)
18% (2)
37% (33)
Other Blood Relative
0% (0)
18% (2)
10% (9)
Unrelated
70% (7)
64% (7)
53% (48)
Blood Type
109
0.914
A
33% (3)
27% (3)
29% (26)
AB
0% (0)
0% (0)
1% (1)
B
11% (1)
0% (0)
12% (11)
O
56% (5)
73% (8)
57% (51)
Rejection
111
30% (3)
36% (4)
9% (8)
0.012
Rejection Type
15
0.006
Acute Antibody Mediated Rejection
100% (3)
25% (1)
0% (0)
Acute Cellular Rejection
0% (0)
75% (3)
100% (8)
Graft Survival
91
100% (7)
100% (9)
98.6% (74)
0.331
Discussion
This single center retrospective analysis of 111 living kidney transplants investigated the influence of recipient and donor intra-operative hemodynamics on first week post-transplant graft function. To our knowledge this is the first study to look at both recipient and donor intra-operative variables and their impact on DGF. The incidence of DGF in our study was comparable to rates reported in the literature for living kidney transplants, being at approximately 4-16% Contrary to previous work in this field we determined a lower post-perfusion central venous pressure appears to be favorable to reduce the incidence of DGF. This may suggest a contributory role from venous hypertension resulting in renal congestion with resultant reduced glomerular filtration rate, local hypoxia and a pro-inflammatory state While we found no association with DGF and intra-operative blood pressure, it should also be recognized that there is no consensus definition for intra-operative hypotension Our findings that fluid volume, use of Lasix, albumin or mannitol has no effect are consistent with the multiple differing results observed in the literature. There is general agreement that preventing intra-vascular depletion is pertinent. However, there is no agreed upon volume, as many factors come into play such as, but not limited to, length of case, recipient body mass, cardiovascular co-morbidities, type of fluid, and fluid adjuncts. Additionally, volume is often described in terms of CVP, which is not always an accurate surrogate for volume status. It is interesting to note that, although not statistically significant, the poor function groups received the lowest amount of intra-operative fluid despite having the higher CVP measurements. In our retrospective study the cause for this is difficult to qualify as multiple factors such as cardiac function, pre-operative volume overload and anesthesia approach may be at play. Perhaps the observation that slightly more patients in the DGF group received albumin and thus had less third spacing may have had an impact. In our study 13.5% of patients experienced acute rejection, and there was a statistical association with poor function, which is consistent with a previously published meta-analysis Our study has certain limitations. First, this was a single center retrospective analysis, and perhaps not representative of the more inclusive experience among transplant centers in the US. Second, there is no protocol in place at our institution for frequency and timing of hemodynamic evaluation, thus standardized measuring of parameters were not available. Third, we had very few cases of DGF, which potentially hindered our ability to detect all risk factors and their strength of association. Also, we did not have baseline resting pulmonary artery and right heart pressures on all patients, nor could we control for the anesthesiologist s approach to hemodynamic management during the case.Lastly, we only looked at outcomes at the 1 year time point which may not truly reflect the long term adverse effects of DGF.
Conclusion
A living kidney transplant is an excellent option for patients with end stage renal disease. Yet recipients of living donor kidneys are still at risk of delayed graft function. Knowledge of baseline cardiac pressures and pre-operative volume status may be of added benefit. Further attention by the surgeon and anesthesiologist to intra-operative hemodynamics during transplantation may help reduce delayed graft function. Specifically, consideration should be given to avoiding an overly aggressive central venous pressure, perhaps with the aid of other invasive means of hemodynamic monitoring such as pulmonary artery catheters or trans-esophageal echo. This recommendation is supported both by our data and other studies in the literature. More importantly, the lack of consensus in defining optimal intra-operative hemodynamics begs the need for larger prospective randomized trials.